| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/175.3.638 |
| P698 | PubMed publication ID | 9041336 |
| P2093 | author name string | T L Noah | |
| H R Black | |||
| P W Cheng | |||
| R E Wood | |||
| M W Leigh | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| bronchoalveolar lavage | Q927148 | ||
| P304 | page(s) | 638-647 | |
| P577 | publication date | 1997-03-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis | |
| P478 | volume | 175 |
| Q40473573 | A Pseudomonas aeruginosa hepta-acylated lipid A variant associated with cystic fibrosis selectively activates human neutrophils. |
| Q42066758 | Abnormalities in the pulmonary innate immune system in cystic fibrosis |
| Q37383069 | Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells |
| Q47449899 | Airway inflammation and infection in congenital bilateral absence of the vas deferens |
| Q36169103 | Airway remodelling in children with cystic fibrosis |
| Q37188760 | Anti-inflammatory therapies for cystic fibrosis-related lung disease |
| Q37201467 | Antibiotic and anti-inflammatory therapies for cystic fibrosis |
| Q36294520 | Assessment of hypoxia in children with cystic fibrosis. |
| Q35132254 | Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice |
| Q36029875 | Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase |
| Q80819585 | Cell and cytokine profile in nasal secretions in cystic fibrosis |
| Q42005356 | Ceramide in cystic fibrosis: a potential new target for therapeutic intervention |
| Q36981240 | Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling |
| Q35059259 | Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema |
| Q38911644 | Cystic Fibrosis: Microbiology and Host Response |
| Q35810067 | Cystic fibrosis transmembrane conductance regulator does not affect neutrophil migration across cystic fibrosis airway epithelial monolayers |
| Q36623329 | Cystic fibrosis: a mucosal immunodeficiency syndrome. |
| Q73873093 | Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes |
| Q44807764 | Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway |
| Q46835722 | Differential regulation of IL-8 by IL-1beta and TNFalpha in hyaline membrane disease |
| Q40398640 | Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding. |
| Q39567122 | Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms. |
| Q74012597 | Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells |
| Q44791790 | Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients |
| Q42728646 | Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis |
| Q54621653 | Enhanced IgE allergic response to Aspergillus fumigatus in CFTR-/- mice. |
| Q26744381 | Epithelial Anion Transport as Modulator of Chemokine Signaling |
| Q48247526 | Evidence for the Involvement of Lipid Rafts and Plasma Membrane Sphingolipid Hydrolases in Pseudomonas aeruginosa Infection of Cystic Fibrosis Bronchial Epithelial Cells. |
| Q37375775 | Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa |
| Q39678214 | Expression of wild-type CFTR suppresses NF-kappaB-driven inflammatory signalling |
| Q35228672 | GBA2-encoded β-glucosidase activity is involved in the inflammatory response to Pseudomonas aeruginosa. |
| Q45858114 | IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia |
| Q36241432 | Identifying novel endpoints for cystic fibrosis clinical trials |
| Q37125716 | Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis |
| Q45723562 | Impaired Innate Host Defense Causes Susceptibility to Respiratory Virus Infections in Cystic Fibrosis |
| Q34007570 | Induction of proinflammatory cytokines from human respiratory epithelial cells after stimulation by nontypeable Haemophilus influenzae |
| Q35684772 | Induction of type I interferon signaling by Pseudomonas aeruginosa is diminished in cystic fibrosis epithelial cells. |
| Q51698037 | Influence of gender and interleukin-10 deficiency on the inflammatory response during lung infection with Pseudomonas aeruginosa in mice. |
| Q35973303 | Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. |
| Q37494912 | Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered |
| Q41996608 | Intestinal inflammation in cystic fibrosis |
| Q42365379 | Linoleic acid supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr-/- transgenic mice |
| Q55104275 | Long-term dietary (n-3) polyunsaturated fatty acids show benefits to the lungs of Cftr F508del mice. |
| Q37264720 | Loss of CFTR results in reduction of histone deacetylase 2 in airway epithelial cells |
| Q37629828 | Mechanism of fibroblast inflammatory responses to Pseudomonas aeruginosa elastase |
| Q34773489 | Monitoring inflammation in CF. Cytokines |
| Q39960094 | Oxidative stress causes IL8 promoter hyperacetylation in cystic fibrosis airway cell models |
| Q36032639 | Pathogen-host interactions in Pseudomonas aeruginosa pneumonia |
| Q37986573 | Pathogenesis and management of nasal polyposis in cystic fibrosis. |
| Q36846425 | Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium |
| Q35012421 | Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis |
| Q39575146 | Phospholipase C-β3 is a key modulator of IL-8 expression in cystic fibrosis bronchial epithelial cells |
| Q35557381 | Potential of anti-inflammatory treatment for cystic fibrosis lung disease |
| Q37131650 | Proteases and cystic fibrosis |
| Q73895312 | Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa |
| Q26341680 | Reduced interleukin-8 production by cystic fibrosis airway epithelial cells |
| Q35842184 | Regulation of gap junctional communication by a pro-inflammatory cytokine in cystic fibrosis transmembrane conductance regulator-expressing but not cystic fibrosis airway cells. |
| Q35506822 | Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis |
| Q64258896 | Remodeling of O Antigen in Mucoid Pseudomonas aeruginosa via Transcriptional Repression of |
| Q37144372 | Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice |
| Q34272231 | Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation |
| Q33877139 | Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis |
| Q64084919 | Roles, Actions, and Therapeutic Potential of Specialized Pro-resolving Lipid Mediators for the Treatment of Inflammation in Cystic Fibrosis |
| Q35753331 | Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro |
| Q35139399 | Serine proteases degrade airway mucins in cystic fibrosis |
| Q44248035 | Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis |
| Q36891552 | Sputum biomarkers of inflammation in cystic fibrosis lung disease |
| Q24802489 | State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? |
| Q33765010 | TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells. |
| Q35808789 | The Effects of CFTR and Mucoid Phenotype on Susceptibility and Innate Immune Responses in a Mouse Model of Pneumococcal Lung Disease. |
| Q35043484 | The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential |
| Q34302923 | The emerging role of flexible bronchoscopy in pediatrics |
| Q43224320 | The inhibition of superoxide production by the soluble phase of cystic fibrosis sputum |
| Q50849208 | The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. |
| Q34773499 | The role of inflammation in the pathophysiology of CF lung disease |
| Q34131911 | The role of inhaled corticosteroids in the management of cystic fibrosis |
| Q37421287 | The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease |
| Q35554386 | Update on pathogenesis of cystic fibrosis lung disease |
| Q35143420 | Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset |
| Q39216925 | Whey protein hydrolysates decrease IL-8 secretion in lipopolysaccharide (LPS)-stimulated respiratory epithelial cells by affecting LPS binding to Toll-like receptor 4. |
| Q93936623 | [In Process Citation] |
| Q81932710 | [Measurement of pulmonary inflammation in cystic fibrosis] |
Search more.